THE SAGE GROUP Announces Publication of Estimates of Critical Limb Ischemia (CLI) Prevalence by Rutherford Category
Published: Jan 11, 2018
“CLI is the most severe and deadly form of peripheral artery disease (PAD),” stated Mary L. Yost, President of THE SAGE GROUP. “According to our estimates, 2.0 to 3.4 million U.S. citizens have CLI. U.S. In general, CLI estimates are sparse. To our knowledge no other estimates of disease prevalence by Rutherford Category have been published.”
“The Rutherford system categorizes CLI by severity into three stages: rest pain (R-4), nonhealing ulcers (R-5) and gangrene (R-6). Mortality and the risk of amputation increase with Rutherford Category. Treatment costs also increase with disease severity. Yet before this analysis, basic data was lacking on how many of those with CLI have rest pain, ulcers and gangrene,” Yost observed.
Commenting on costs, Yost stated, “Over the last 10 years, CLI patients have increased as a percentage of PAD patients treated. Since treatment costs increase with severity, this is a significant factor driving PAD costs upward.”
About the Report: United States Critical Limb Ischemia by Rutherford Category
Prevalence and Markets in Patients and Limbs
This report contains a comprehensive analysis of the U.S. prevalence of CLI by Rutherford Category for the 2015-2030 periods. Estimates begin with THE SAGE GROUP’S high and low series of CLI numbers.
The percentage prevalence of CLI patients in each Rutherford Category reflects recently published peer-reviewed data. Within each Rutherford Category, patients are assumed to be treated with revascularization, amputation or palliative therapies. Patient prevalence by treatment pathway is projected for each Rutherford Category for 2015-2030.
Since only a fraction of patients is diagnosed and treated, the current market, or those treated, is estimated by treatment pathway for each Rutherford Category.
Because CLI is commonly bilateral, all estimates are also made for limbs as well as for patients.
Additional information: http://thesagegroup.us/pages/reports/cli-us-rutherford.php.
THE SAGE GROUP, a research and consulting company, specializes in peripheral vascular disease in the lower limbs, specifically chronic venous disease (CVD), PAD, CLI, intermittent claudication (IC), diabetic foot ulcers (DFU) and the costs and consequences of PAD and amputation. Additional information: www.thesagegroup.us.
THE SAGE GROUP
Harrington Witherspoon, 404-816-0746
Source: THE SAGE GROUP